Parkman Healthcare Partners LLC Acquires New Stake in Stoke Therapeutics, Inc. $STOK

Posted by Brenda Bartman on Aug 25th, 2026

Parkman Healthcare Partners LLC acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 355,443 shares of the company’s stock, valued at approximately $11,630,000.

A number of other large investors also recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in shares of Stoke Therapeutics in the 4th quarter worth $26,000. Quantbot Technologies LP acquired a new position in shares of Stoke Therapeutics during the second quarter worth about $34,000. KBC Group NV acquired a new position in shares of Stoke Therapeutics during the first quarter worth about $36,000. Harbour Investments Inc. raised its holdings in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares in the last quarter. Finally, Western Wealth Management LLC purchased a new position in Stoke Therapeutics during the first quarter worth about $55,000.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the transaction, the director directly owned 124,557 shares of the company’s stock, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 4,767 shares of Stoke Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $152,687.01. Following the transaction, the insider directly owned 25,655 shares of the company’s stock, valued at approximately $821,729.65. This represents a 15.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 30,623 shares of company stock valued at $953,765 in the last quarter. 9.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. assumed coverage on Stoke Therapeutics in a report on Friday. They issued an “overweight” rating and a $40.00 price objective on the stock. Wedbush raised their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Canaccord Genuity Group dropped their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective for the company. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.25.

Read Our Latest Stock Report on Stoke Therapeutics

Stoke Therapeutics Trading Up 0.1%

STOK stock opened at $32.32 on Tuesday. The company has a market cap of $2.09 billion, a P/E ratio of -9.68 and a beta of 1.20. Stoke Therapeutics, Inc. has a 52 week low of $18.00 and a 52 week high of $40.22. The company’s 50-day moving average price is $31.04 and its 200 day moving average price is $32.23.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The company had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current year.

Stoke Therapeutics Profile

(Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.